Novo Nordisk parent refiles US application on Catalent deal (updated)

Catalent

08/04/2024 11:28

(Adds detail in paragraphs 2-5)
       COPENHAGEN, April 8 (Reuters) - The parent of Wegovy
producer Novo Nordisk  NOVOb.CO  has refiled an application to
the U.S. Federal Trade Commission (FTC) for approval of a $16.5
billion deal to buy manufacturing subcontractor Catalent
 CTLT.N , a spokesperson said on Monday. 
    Novo Nordisk Foundation said last month it had agreed to buy
Catalent to boost output of the weight-loss drug Wegovy. After
the deal closes, it would sell three of Catalent's fill-finish
sites on to Novo Nordisk for $11 billion.
    An application was submitted to U.S. anti-trust authorities
on March 4. But "following informal discussions with the FTC
staff", the company withdraw and filed a new application on
April 2, a Catalent SEC filing dated April 3 showed.
    A Novo Foundation spokesperson confirmed to Reuters that the
company "has resubmitted the application to give authorities
more time".
    Novo had said the deal was expected to be completed towards
the end of 2024. The spokesperson declined to comment on whether
that was still possible and also declined to comment on why the
application had been refiled.

 (Reporting by Jacob Gronholt-Pedersen, writing by Stine
Jacobsen; editing by Anna Ringstrom and Jason Neely)
 ((stine.jacobsen@thomsonreuters.com; +45 21 56 90 10;))